The correlation coefficient, CC, was all/weak: 45.69/32.02 and Patterson figure of merit, PATFOM: 2.94. The selenium sites were refined along with additional 5 selenium sites identified and initial phases were calculated to overall figure of merit of 0.33 with the program ADDSOLVE [50]. Further, phases were improved to a figure of merit of 0.53 using solvent flattening and twelve-fold non-crystallographic symmetric averaging (NCS) in RESOLVE [51] which yielded a partial model. The electron density

map was further improved by using single wavelength (Se peak) data as the starting point in the MRSAD anomalous dispersion protocol of the auto-rickshaw software pipeline which improved the Selumetinib cost model substantially [52]. Several rounds of manual model building with Coot [53] and refinement with the program REFMAC5 [54] and [55] were carried out. The final model (R = 0.207, Rfree = 0.273) contains 5352 residues isocitrate dehydrogenase phosphorylation from 12 molecules in asymmetric unit (446aa × 12mols) along with six lysine and seven aspartate molecules. The model quality was monitored using

PROCHECK [56]. The coordinates and structure factors were deposited in the RCSB Protein Data Bank under accession code 3TVI. Table 1 and Table 2 details our data collection and refinement statistics. Structural presentation was generated using the program PyMol. The solvent-accessible surface of monomers, dimer and tetramers as well as their interacting interface was analyzed by PISA server [57]. Protein domain motions were analyzed by using the DynDom server [58]. We thank the beamline staff (Mike Sullivan, John Toomey, and Don Abel) of the Center for Synchrotron Biosciences. We wish to thank Jacqueline Freeman for cloning, Kevin Bain for protein expression, Davin Henderson for protein purification, and Elena Fedorova for initial technical assistance with robotic crystallization screening. This research is supported by the Biomedical Enzalutamide concentration Technology Resource Program of the National Institute for Biomedical Imaging

and Bioengineering under P41-EB-01979 and P30-EB-09998 and a Protein Structure Initiative grant to the NYSGXRC funded by the National Institute for General Medical Sciences under U54-GM-74945. We thank Dr. J. Michael Sauder (Lilly Biotechnology Center, 10300 Campus Point Dr, San Diego, CA, USA) and Dr. Ranaud Dumas, (Laboratoire de Physiologie Cellulaire & Végétale, CEA, CNRS, INRA, UJF, UMR 5168, 38054 Grenoble, France) for critical reading and comments on this manuscript. “
“Emulsifiers and surfactants are widely used in the petroleum, pharmaceuticals, cosmetics, foods, environmental protection and crude oil recovery. The biosurfactants are making their place in surfactants market due to their lower toxicity, biodegradability, selectively and specific activity at extreme environmental conditions [19].